


COX-2-IN-23

Cat. No.:	HY-147961
CAS No.:	2417995-08-3
Molecular Formula:	C ₂₄ H ₂₅ N ₅ O ₃ S ₂
Molecular Weight:	495.62
Target:	COX
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC ₅₀ values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity.									
IC₅₀ & Target	COX-2 0.28 μM (IC ₅₀)	COX-1 20.14 μM (IC ₅₀)								
In Vivo	<p>COX-2-IN-23 (compound 9a) (9 mg/kg; a single i.p.; 0-4 hours) exhibits anti-inflammatory activities and lowest incidence of pepticulcer^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mature male albino rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>9 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 0, 1, 2, 3 and 4 hours.</td> </tr> <tr> <td>Result:</td> <td>Had similar ulcerogenic activity to celecoxib.</td> </tr> </table>		Animal Model:	Mature male albino rats ^[1]	Dosage:	9 mg/kg	Administration:	Intraperitoneal injection; 0, 1, 2, 3 and 4 hours.	Result:	Had similar ulcerogenic activity to celecoxib.
Animal Model:	Mature male albino rats ^[1]									
Dosage:	9 mg/kg									
Administration:	Intraperitoneal injection; 0, 1, 2, 3 and 4 hours.									
Result:	Had similar ulcerogenic activity to celecoxib.									

REFERENCES

[1]. Ibrahim TS, et al. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on bumetanide scaffold. *Bioorg Chem.* 2020 Jul;100:103878.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA